RU2009116632A - Энантиомер кетоконазола у людей - Google Patents
Энантиомер кетоконазола у людей Download PDFInfo
- Publication number
- RU2009116632A RU2009116632A RU2009116632/15A RU2009116632A RU2009116632A RU 2009116632 A RU2009116632 A RU 2009116632A RU 2009116632/15 A RU2009116632/15 A RU 2009116632/15A RU 2009116632 A RU2009116632 A RU 2009116632A RU 2009116632 A RU2009116632 A RU 2009116632A
- Authority
- RU
- Russia
- Prior art keywords
- patient
- ketoconazole
- enantiomer
- hmg
- coa reductase
- Prior art date
Links
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical class C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 title claims abstract 30
- 238000000034 method Methods 0.000 claims abstract 31
- 229960004125 ketoconazole Drugs 0.000 claims abstract 26
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract 12
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims abstract 12
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 claims abstract 8
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 8
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims abstract 6
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims abstract 5
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims abstract 5
- 229960005370 atorvastatin Drugs 0.000 claims abstract 5
- 239000003112 inhibitor Substances 0.000 claims abstract 4
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 claims abstract 2
- 206010061218 Inflammation Diseases 0.000 claims abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract 2
- 229940123934 Reductase inhibitor Drugs 0.000 claims abstract 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract 2
- 230000004054 inflammatory process Effects 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 230000009885 systemic effect Effects 0.000 claims abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 8
- 235000012000 cholesterol Nutrition 0.000 claims 4
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 238000008214 LDL Cholesterol Methods 0.000 claims 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 claims 2
- 229960003765 fluvastatin Drugs 0.000 claims 2
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 229960004844 lovastatin Drugs 0.000 claims 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 229960002797 pitavastatin Drugs 0.000 claims 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 2
- 229960002965 pravastatin Drugs 0.000 claims 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 2
- 229960000672 rosuvastatin Drugs 0.000 claims 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 2
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 claims 2
- 229960002855 simvastatin Drugs 0.000 claims 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 230000003908 liver function Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84896306P | 2006-10-02 | 2006-10-02 | |
| US60/848,963 | 2006-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009116632A true RU2009116632A (ru) | 2010-11-10 |
Family
ID=39269161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009116632/15A RU2009116632A (ru) | 2006-10-02 | 2007-10-02 | Энантиомер кетоконазола у людей |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9198906B2 (OSRAM) |
| EP (1) | EP2076265A4 (OSRAM) |
| JP (1) | JP2010505866A (OSRAM) |
| AU (1) | AU2007303219A1 (OSRAM) |
| BR (1) | BRPI0719835A2 (OSRAM) |
| CA (1) | CA2664800A1 (OSRAM) |
| IL (1) | IL197986A0 (OSRAM) |
| NO (1) | NO20091593L (OSRAM) |
| NZ (1) | NZ576569A (OSRAM) |
| RU (1) | RU2009116632A (OSRAM) |
| WO (1) | WO2008042898A2 (OSRAM) |
| ZA (1) | ZA200902127B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200706020B (en) * | 2005-01-10 | 2008-12-31 | Cortendo Invest Ab Publ | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
| WO2007081980A2 (en) * | 2006-01-10 | 2007-07-19 | Diobex, Inc. | Methods and compositions for treating prostate cancer |
| CA2664800A1 (en) | 2006-10-02 | 2008-04-10 | Timothy Andrew Stewart | Ketoconazole enantiomer in humans |
| EP3049084A4 (en) * | 2013-09-25 | 2017-03-15 | Cortendo AB (publ) | Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibitng cytochrome p450 inhibition |
| WO2016048984A1 (en) * | 2014-09-25 | 2016-03-31 | Cortendo Ab (Publ) | Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole |
| WO2020180784A1 (en) * | 2019-03-04 | 2020-09-10 | Strongbridge Dublin Limited | Methods of treating disease with levoketoconazole |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4144346A (en) | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
| US4503055A (en) | 1979-03-26 | 1985-03-05 | Janssen Pharmaceutica, N.V. | Derivatives of [4-(piperazin-1-yl-phenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles |
| US4814333A (en) | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| US5432176A (en) | 1988-11-29 | 1995-07-11 | The John Hopkins University | Method of retarding the progression of chronic renal failure |
| WO1994014447A1 (en) * | 1992-12-22 | 1994-07-07 | Sepracor, Inc. | Methods and compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections |
| AU5851594A (en) | 1992-12-22 | 1994-07-19 | Georgetown University | Methods and compositions of (+) ketoconazole for treating fungal, yeast and dermatophyte infections |
| IL109728A0 (en) | 1993-05-28 | 1994-08-26 | Pfizer Res & Dev | Indoles |
| US5869255A (en) | 1994-02-01 | 1999-02-09 | The Regents Of The University Of California | Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis |
| PT779810E (pt) | 1994-08-09 | 2003-11-28 | Cortendo Ab | Utilizacao de cetoconazole e substancias relacionadas em medicamentos para o tratamento da diabetes tipo ii |
| US6642236B1 (en) | 1998-12-14 | 2003-11-04 | Cortendo Ab | Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis |
| US5584790A (en) | 1995-09-08 | 1996-12-17 | Beckman Instruments, Inc. | Variable inclination centrifugation assembly for rapid separation of blood |
| CA2240115A1 (en) | 1995-12-14 | 1997-06-19 | Wallace T. Ashton | Antagonists of gonadotropin releasing hormone |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| SE9700642D0 (sv) | 1997-02-24 | 1997-02-24 | Kronvall Stefan Med Ab | Medel och sätt för förebyggande och behandling av det metabola syndromet |
| BR9810378A (pt) | 1997-07-01 | 2000-08-29 | Novo Nordisk As | Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドｇｌｐ−１アゴニスト |
| DE60012721T4 (de) | 1999-03-29 | 2010-09-09 | Uutech Ltd., Coleraine | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes |
| JP2002541146A (ja) | 1999-04-02 | 2002-12-03 | ニューロゲン コーポレイション | アリールおよびヘテロアリール融合のアミノアルキル−イミダゾール誘導体および糖尿病薬としてのその使用 |
| BR0010651A (pt) | 1999-05-17 | 2002-03-19 | Novo Nordisk As | Composto, uso de um composto, composição farmacêutica, e, método para o tratamento e/ou prevenção de distúrbios ou de doenças mediadas por uma ação antagonìstica de glucagon |
| GB9915625D0 (en) | 1999-07-02 | 1999-09-01 | Cortendo Ab | Method |
| AU7726600A (en) | 1999-09-28 | 2001-04-30 | Bayer Corporation | Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use |
| GB0001449D0 (en) | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
| US20020055512A1 (en) | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
| AU2001268661A1 (en) | 2000-06-27 | 2002-01-08 | Aventis Pharma S.A. | 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase |
| GB0118300D0 (en) | 2001-07-26 | 2001-09-19 | Cortendo Ab | Formulations |
| US20040265827A1 (en) | 2001-09-21 | 2004-12-30 | Zhimin Zhu | Regulation of human steroid 5-alpha reductase |
| CA2459926A1 (en) | 2001-09-24 | 2003-04-03 | Merck & Co., Inc. | Screening and selection methods for statin drug combinations |
| WO2003027094A2 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
| AU2003205926A1 (en) | 2002-02-07 | 2003-09-02 | Pfizer Limited | Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome |
| AU2003256988A1 (en) | 2002-12-11 | 2004-06-30 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| US20040180868A1 (en) * | 2003-03-12 | 2004-09-16 | Mullally John P. | Composition and method for treating inflammations by reducing C-reactive protein |
| WO2005113516A1 (en) | 2004-05-14 | 2005-12-01 | Neurocrine Biosciences, Inc. | Uracil-type gonadotropin-releasing hormone receptor antagonists and methods related thereto |
| US20060002999A1 (en) | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| ZA200706020B (en) | 2005-01-10 | 2008-12-31 | Cortendo Invest Ab Publ | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
| US20070116839A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith |
| WO2007081980A2 (en) | 2006-01-10 | 2007-07-19 | Diobex, Inc. | Methods and compositions for treating prostate cancer |
| CA2664800A1 (en) | 2006-10-02 | 2008-04-10 | Timothy Andrew Stewart | Ketoconazole enantiomer in humans |
| US9394290B2 (en) | 2010-10-21 | 2016-07-19 | Universitaet Des Saarlandes Campus Saarbruecken | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases |
-
2007
- 2007-10-02 CA CA002664800A patent/CA2664800A1/en not_active Abandoned
- 2007-10-02 WO PCT/US2007/080186 patent/WO2008042898A2/en not_active Ceased
- 2007-10-02 ZA ZA200902127A patent/ZA200902127B/xx unknown
- 2007-10-02 RU RU2009116632/15A patent/RU2009116632A/ru not_active Application Discontinuation
- 2007-10-02 JP JP2009531558A patent/JP2010505866A/ja active Pending
- 2007-10-02 US US12/443,531 patent/US9198906B2/en active Active
- 2007-10-02 BR BRPI0719835-3A2A patent/BRPI0719835A2/pt not_active IP Right Cessation
- 2007-10-02 NZ NZ576569A patent/NZ576569A/en not_active IP Right Cessation
- 2007-10-02 EP EP07868351A patent/EP2076265A4/en not_active Withdrawn
- 2007-10-02 AU AU2007303219A patent/AU2007303219A1/en not_active Abandoned
-
2009
- 2009-04-05 IL IL197986A patent/IL197986A0/en unknown
- 2009-04-22 NO NO20091593A patent/NO20091593L/no not_active Application Discontinuation
-
2015
- 2015-11-18 US US14/944,258 patent/US20160067243A1/en not_active Abandoned
-
2018
- 2018-01-09 US US15/865,631 patent/US20180125841A1/en not_active Abandoned
-
2019
- 2019-03-13 US US16/351,797 patent/US20190209555A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ576569A (en) | 2012-05-25 |
| AU2007303219A1 (en) | 2008-04-10 |
| US20160067243A1 (en) | 2016-03-10 |
| EP2076265A4 (en) | 2010-09-22 |
| WO2008042898A2 (en) | 2008-04-10 |
| WO2008042898A9 (en) | 2008-09-04 |
| US20100093755A1 (en) | 2010-04-15 |
| BRPI0719835A2 (pt) | 2014-05-06 |
| NO20091593L (no) | 2009-04-22 |
| IL197986A0 (en) | 2009-12-24 |
| EP2076265A2 (en) | 2009-07-08 |
| US20190209555A1 (en) | 2019-07-11 |
| CA2664800A1 (en) | 2008-04-10 |
| WO2008042898A3 (en) | 2008-10-23 |
| US20180125841A1 (en) | 2018-05-10 |
| US9198906B2 (en) | 2015-12-01 |
| ZA200902127B (en) | 2010-07-28 |
| JP2010505866A (ja) | 2010-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Catapano et al. | Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients | |
| Davidson et al. | Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo‐controlled, blinded experience in 2382 patients with primary hypercholesterolemia | |
| Cho et al. | Design and rationale of the GAUSS‐2 study trial: a double‐blind, ezetimibe‐controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy | |
| BG107811A (bg) | Използване на розувастатин (zd-4522) за лечение на хетерозиготна наследствена хиперхолестеролемия | |
| JP2010505866A5 (OSRAM) | ||
| Greer et al. | Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure | |
| IL310115A (en) | Treatment of his hyporesponders | |
| Sahu et al. | Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection | |
| CA2679416A1 (en) | Combination therapy, composition and methods for the treatment of cardiovascular disorders | |
| Mikhailidis et al. | The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study | |
| Shepherd | Dyslipidaemia in diabetic patients: time for a rethink | |
| NZ576569A (en) | Ketoconazole enantiomer in humans | |
| US20110275649A1 (en) | Combination therapy for the prevention of statin induced diabetes | |
| Bayes et al. | Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients | |
| Wang et al. | A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol | |
| Derosa et al. | Efficacy and safety of ezetimibe/simvastatin association on non‐diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment | |
| Chou et al. | Effect of 1PC111, a fixed-dose combination of pitavastatin and ezetimibe, versus pitavastatin or ezetimibe monotherapy on lipid profiles in patients with hypercholesterolemia or mixed dyslipidemia: A randomized, double-blind, multicenter, Phase III study | |
| KR101401253B1 (ko) | Ｐｃｓｋ9 발현 억제를 통한 저밀도지단백 수용체 증가 유도용 조성물 | |
| RU2007149337A (ru) | Новый способ лечения гиперлипидемии | |
| Polman et al. | Statins for the treatment of multiple sclerosis: cautious hope | |
| Goldberg et al. | 1084-174 Efficacy of ezetimibe-10 mg/day coadministered with multiple doses of simvastatin in patients with primary hypercholesterolemia | |
| Shakir et al. | Novel Role of Irbesartan in Elevating Serum High Density Lipoprotein in Hypercholesterolemic Animal Model | |
| Al-Saadawi | Modern principles of using inhibitors of the HMG-CoA reductase (statins) in the practice of the clinical hospital | |
| Ballantyne et al. | 1084-176 Efficacy of ezetimibe coadministered with simvastatin versus atorvastatin in patients with hypercholesterolemia | |
| Baker | Managing Hyperlipidemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110328 |